Our People


President Message

Before the BIO revolution called the “Human Genome Project” (HGP), it was believed that EXON was the most important part of the chromosome. However, after HGP was completed and the biotech industry flourished, the importance of the INTRON became widely recognized. There continues to be extensive research on the importance of the INTRON today.

iNtRON Biotechnology originated from the concept of INTRON itself. iNtRON strives to be the true worldwide leader in biotechnology in life engineering. The company was established based on this goal and it remains the vision of iNtRON Biotechnology to this day. And more, iNtRON’s “it” contains our dream and vision.

iNtRON started as a research reagents company in 1999. Later, the molecular diagnostic business was added. The company became a leading diagnostic company which was renowned for its New Flu diagnostic Kit.

And then, after developing platform technology related to Bacteriophage and Endolysin, the company passed a technology evaluation by the Korea Exchange (KRX) in 2010. Then in January 2011, iNtRON finally had its first IPO and was listed on the KOSDAQ. The company is continuously searching for ways to improve and innovate in pursuit of its goal of becoming the world’s best biotechnology company.

iNtRON is looking for the answer from “Global R&BD Group”. R&D is our top priority, and we believe it is possible to leap forward to a global company if we focus on Research & Business Development (R&BD) for new drug development. With this belief, we aim to become a "global R&BD group."

iNtRON’s New Drug R&D is focused on 1) Humans 2) Medicines for Diseases 3) First-in-Class & First-in-Concept (MOA based)

iNtRON is continuously striving to develop not only new Blockbuster drugs, but new Moral-Buster drugs as well. In addition to that, the new drug technology used as a base for this development will focus on discovering First-in-Class & First-in-Concept new drug candidate substances which MOA proves.

With the belief that “Only Passion Makes Me Free!” and “不狂不及, 磨斧作針, 熱血男兒” spirit we will become a leading “Global R&BD Group”, who, based on our dedication and tireless effort, will show exceptional results on a continuous basis.

YOON, Seong Jun

CEO Message


iNtRON is developing new drugs based on bacteriophages covering therapeutic areas from superbug treatments to immunotherapeutics.

'Bacteriophage is a bacteria eating virus.‘ That’s why most companies and researchers have been applying bacteriophages to the development of drugs for Bacterial Infectious Diseases.

However, iNtRON is different!

iNtRON is developing novel drugs to treat bacterial infectious diseases based on Endolysins derived from bacteriophages. The reason iNtRON does not target bacterial infectious diseases with bacteriophages itself, is that while bacteriophages are ‘bacteria eating virus,' they don't ‘completely eat up bacteria.' However, Endolysins derived from bacteriophages can 'completely kill bacteria‘, which is why iNtRON focuses on the development of Endolysin and it’s engineering itLysin® technology for the bacterial infectious disease field, rather than solely relying on bacteriophages.

Meanwhile, iNtRON is developing new microbiome (phageome) drugs utilizing bacteriophages. iNtRON is developing new drugs (PHAGERIA®) that can kill harmful bacteria in the gut since bacteriophages can target gut microbiome as bacteria eating virus, promote a healthy gut microbiota, and prevent and treat various diseases caused by harmful bacteria.

Furthermore, as bacteriophage is a type of virus, iNtRON is developing antiviral technology (PHAGERUS®) to neutralize viruses. This technology can be used to develop vaccines and antiviral treatments.

Moreover, iNtRON newly envisions bacteriophages as living creatures involved in immunity. The human body is composed of countless types and numbers of bacteria, viruses and also bacteriophages, and it's like a universe that highly diverse interactions are happening among them. While previous research has been rooted in the proposition 'Bacteriophage = bacteria killing virus,' the new perspective is to see them as ‘living creatures involved in immunity’ now. iNtRON aims to resolve major challenges in human health and immunity by utilizing bacteriophages as a core key. The platform technology PHAGERIARUS® enables us to expand a field of bacteriophage to the immunity.

‘The coming future is today of tomorrow‘. iNtRON will develop not only ‘First-in-Class’ but also ‘First-in-Concept’ new drugs. Rather than be a follower of existing drugs, we are committed to develop new drugs that lead the world.

Thank you very much.

YOON, Kyung Won
CEO / Vice President

iNtRON Biotechnology, Inc.


Board of Directors
YOON, Seong Jun (Alek)
CEO / President
  • Master of Animal Resource and Science at Seoul National University
  • Worked at the Cancer Research Institute of Seoul National University Hospital
  • Working at iNtRON Biotechnology as CEO, President
YOON, Kyung Won (Kevin)
CEO / Vice President
  • Graduated from Seoul National University in Textile Engineering
  • EMBA at Seoul National University
  • Worked at Samsung C&T Corporation and CITI BANK
  • Working at the Strategic Planning Dept. of iNtRON Biotechnology
KANG, Sang Hyeon Ph.D.
CTO / Vice President
  • Ph.D. in Industrial Engineering Chemistry at Seoul National University
  • Worked at Dreambiogen
  • Working at Lifetech Institute of iNtRON Biotechnology
SEOL, Jae Goo Ph.D.
CTO / Senior Executive Director
  • Ph.D. in Cancer Biology at Seoul National University
  • Worked at the Cancer Research Institute of Seoul National University Hospital
  • Working at DR Biz Dept. of iNtRON Biotechnology
Global Business Team
SHIN, Tae Kyu (TK)
Senior Part Leader/Biz Part
YANG, Hae Dong (James)
Senior Team Leader/Biz Part
Recruitment in Progress (Seongnam, Gyeonggi-Do)
Recruitment in Progress (Burlington, MA)